Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| Nxstage Medical, Inc. (NXTM) Discloses Form 4 Insider Selling : Exec. Jeffrey ... - OTC Outlook |
 |
 |
|
Nxstage Medical, Inc. (NXTM) Discloses Insider Transaction. Jeffrey H Burbank , Chief Executive Officer of Nxstage Medical, Inc. sold 20,000 shares on Jun 17, 2015. The Insider selling transaction was disclosed on Jun 19, 2015 to the Securities and Exchange Commission. The shares were sold at $15.56 per share for a total value of $311,200.00 according to InsiderTradingReport. 12.08% of the shares are held by the company Insiders, 91.2% of the shares are held by the institutions. Company shares has an average 3 month share volume of 477,362 and an average 10 day volume is recorded to be 425,475 The Company has disclosed insider buying and selling activities to the Securities Exchange,The (President) of Nxstage Medical, Inc., Turk Joseph E Jr sold 2,839 shares at $16 on June 10, 2015. The Insider selling transaction had a total value worth of $45,424. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. NxStage Medical, Inc. (NASDAQ:NXTM) witnessed a volatile trading activity on Friday and eventually ended flat at 0% or 0 points without letting the bulls or bears take much advantage. The trading began at $15.75 and reached the intraday high at $15.9. The bulls started the profit booking and pushed the shares to intraday low of $15.67. The trading session was marked by a volume range of 569,907 shares exchanging hands. The 52-week high of the shares is $19.63 and the 52-week low is $11.5. The market cap of the company stands at $993 million and there are 63,238,000 shares in public circulation. The shares of NXTM have rallied 12.35% in the past 52 Weeks. On April 27, 2015 The shares registered one year high of $19.63 and one year low was seen on September 16, 2014 at $11.5. The 50-day moving average is $16.9 and the 200 day moving average is recorded at $17.56. S&P 500 has rallied 8.07% during the last 52-weeks. Several Brokerage firms have commented on company shares. In a research note released to the investors, Canaccord Genuity maintains its rating on NxStage Medical, Inc. (NASDAQ:NXTM).The analysts at the brokerage house have a current rating of Buy on the counter. In a recent information released to the investors, Canaccord Genuity raises the new price target from $24 per share to $27 per share. NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market. |
